Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses

By sjmartinez • November 16, 2022

Ramirez SI, Grifoni A, Weiskopf D, Parikh UM, Heaps A, Faraji F, Sieg SF, Ritz J, Moser CB, Eron JJ, Currier JS, Klekotka P, Sette A, Wohl DA, Daar ES, Hughes MD, Chew KW, Smith DM, Crotty S. Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses. JCI Insight. 2022 Nov 15:e163471. doi: 10.1172/jci.insight.163471. Epub ahead of print. PMID: 36378539.

Tags: Adaptive immunity, covid-19, Immunology, Infectious Diseases, Publications

Rare mycetoma caused by Raghukumaria species, a mangrove-derived dematiaceous fungus in a kidney transplant patient

Gonzalez-Ferrer S, Yanagimoto-Ogawa L, Zhuo R, Matysiak Match CJ, Dayo A, Kang Y, Yang S. Rare mycetoma caused by Raghukumaria species, a mangrove-derived dematiaceous fungus in a[...]

Cannabis use, risk of cannabis use disorder, and anxiety and depression among bisexual patients: A comparative study of sex and sexual identity differences in a large health system

Setrakian N, Gelberg L, Koerber J, Chung UY, Akabike WN, Gorbach PM, Seamans MJ, Shoptaw S, Cerezo A, Javanbakht M. Cannabis use, risk of cannabis[...]

Host targets of candidalysin

Lin J, Filler SG. Host targets of candidalysin. PLoS Pathog. 2025 Jun 23;21(6):e1013284. doi: 10.1371/journal.ppat.1013284. PMID: 40549807; PMCID: PMC12184922.